---
figid: PMC4714660__CAS-106-00000000001659-g001
figtitle: Human dendritic cell (DC) response to Toll‐like receptor (TLR)2/3 adjuvants
organisms:
- Escherichia coli
- Mycobacterium tuberculosis variant bovis BCG
- Bacillus anthracis
- Mycobacterium tuberculosis variant bovis
- Hepatitis B virus
- Human papillomavirus
- Homo sapiens
- Mus musculus
- Chironomus thummi
- NA
organisms_ner:
- Mus musculus
- Homo sapiens
- Danio rerio
pmcid: PMC4714660
filename: CAS-106-00000000001659-g001.jpg
figlink: /pmc/articles/PMC4714660/figure/cas12824-fig-0001/
number: F1
caption: Human dendritic cell (DC) response to Toll‐like receptor (TLR)2/3 adjuvants.
  Human CD141+ DC corresponds to mouse CD8α+ DC, and functions as a main antigen (Ag)‐presenting
  cell. CD141+ DC express the TLR2 family (TLR1, 2, and 6) and TLR3 but does not express
  other TLRs. Hence, this type of antigen‐presenting DC cannot respond to LPS, lipopolysaccharide;
  flagellin, imiquimod, or CpG‐ODN, oligodeoxy nucleotide. TLR2 is surface‐expressed
  and captures its agonists on the membrane whereas TLR3 is expressed in endosomes,
  where TLR3 encounters dsRNA. The TLR3–TLR adaptor molecule‐1 (TICAM‐1) pathway is
  unique in the induction of interleukin (IL)‐12p70 and interferon (IFN)‐independent
  cross‐presentation. Both pathways also accompany inflammation. The possible pathways
  for DC maturation by TLR2 and TLR3 are depicted. DAMPs, damage‐associated molecular
  patterns; HMGB1, high mobility group box protein1; IFNAR, IFN‐α/β receptor; IKK,
  IκB kinase; iNOS, inducible nitric oxide synthase; IRF3, IFN regulatory factor 3;
  MyD88, myeloid differentiation primary response gene 88; NAP1, NF‐κB‐activating
  kinase‐associated protein 1; NF‐κB, nuclear factor‐κB; NK, natural killer; RIP1,
  receptor‐interacting protein kinase 1; ROS, reactive oxygen species; TBK1, TANK‐binfing
  kinase 1; TRAF, TNF receptor‐associated factor. Panel A was quoted from Ref.39.
papertitle: Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor
  2 and 3 agonists for safely enhancing antitumor immunity.
reftext: Tsukasa Seya, et al. Cancer Sci. 2015 Dec;106(12):1659-1668.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8924699
figid_alias: PMC4714660__F1
figtype: Figure
redirect_from: /figures/PMC4714660__F1
ndex: df2e0cea-df0c-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4714660__CAS-106-00000000001659-g001.html
  '@type': Dataset
  description: Human dendritic cell (DC) response to Toll‐like receptor (TLR)2/3 adjuvants.
    Human CD141+ DC corresponds to mouse CD8α+ DC, and functions as a main antigen
    (Ag)‐presenting cell. CD141+ DC express the TLR2 family (TLR1, 2, and 6) and TLR3
    but does not express other TLRs. Hence, this type of antigen‐presenting DC cannot
    respond to LPS, lipopolysaccharide; flagellin, imiquimod, or CpG‐ODN, oligodeoxy
    nucleotide. TLR2 is surface‐expressed and captures its agonists on the membrane
    whereas TLR3 is expressed in endosomes, where TLR3 encounters dsRNA. The TLR3–TLR
    adaptor molecule‐1 (TICAM‐1) pathway is unique in the induction of interleukin
    (IL)‐12p70 and interferon (IFN)‐independent cross‐presentation. Both pathways
    also accompany inflammation. The possible pathways for DC maturation by TLR2 and
    TLR3 are depicted. DAMPs, damage‐associated molecular patterns; HMGB1, high mobility
    group box protein1; IFNAR, IFN‐α/β receptor; IKK, IκB kinase; iNOS, inducible
    nitric oxide synthase; IRF3, IFN regulatory factor 3; MyD88, myeloid differentiation
    primary response gene 88; NAP1, NF‐κB‐activating kinase‐associated protein 1;
    NF‐κB, nuclear factor‐κB; NK, natural killer; RIP1, receptor‐interacting protein
    kinase 1; ROS, reactive oxygen species; TBK1, TANK‐binfing kinase 1; TRAF, TNF
    receptor‐associated factor. Panel A was quoted from Ref.39.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ag
  - Tlr3
  - Cd8a
  - Ticam1
  - Tlr1
  - Tlr2
  - Abi1
  - Napsa
  - Azi2
  - Nckap1
  - Nap1l1
  - Trmo
  - Hmgb1
  - Tlr4
  - Ralbp1
  - Ripk1
  - Myd88
  - Traf3
  - Tlr5
  - Tbk1
  - Ikbkb
  - Ikbke
  - Batf3
  - Tlr6
  - Chuk
  - Ephb2
  - Mapk1
  - Nfkb1
  - Irf3
  - Tlr7
  - Nos2
  - Mapk8
  - Il12b
  - Tlr8
  - Cdk5r1
  - Il12a
  - Upk3b
  - Gchfr
  - Ifna
  - Ifnar1
  - Tlr9
  - S100a1
  - Dh
  - Thbd
  - AN
  - RFTN1
  - TLR3
  - CD8A
  - TRAF1
  - TRAF2
  - TRAF3
  - TRAF4
  - TRAF5
  - TRAF6
  - TRAF7
  - TICAM1
  - TLR1
  - TLR2
  - CXCL8
  - NAP1L1
  - NAPSA
  - ACOT8
  - NCKAP1
  - TRMO
  - AZI2
  - NAA25
  - TAB3
  - HMGB1
  - TLR4
  - UQCRFS1
  - RIPK1
  - RALBP1
  - KRR1
  - MYD88
  - TLR5
  - TBK1
  - IKBKB
  - IKBKE
  - BATF3
  - TLR6
  - CHUK
  - EPHB2
  - MAPK1
  - MAPK3
  - NFKB1
  - IRF3
  - TLR7
  - NOS2
  - ISYNA1
  - MAPK8
  - MAPK9
  - MAPK10
  - TLR8
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - FCN2
  - GCHFR
  - IL12A
  - CDK5R1
  - UPK3B
  - IFNA1
  - IFNAR1
  - IFNAR2
  - TLR9
  - S100A1
  - S100B
  - S100G
  - S100P
  - S100Z
  - HRNR
  - S100A10
  - S100A11
  - S100A12
  - S100A13
  - S100A14
  - S100A16
  - S100A2
  - S100A3
  - S100A4
  - S100A5
  - S100A6
  - S100A7
  - S100A7A
  - S100A8
  - S100A9
  - TCHHL1
  - TLR10
  - THBD
  - tlr3
  - cd8a
  - ticam1
  - tlr1
  - tlr2
  - azi2
  - hmgb1a
  - ripk1l
  - myd88
  - traf3
  - tlr5b
  - tbk1
  - batf3
  - irf3
  - tlr7
  - nos1
  - mapk8b
  - cdk5r1b
  - tlr9
---
